FDA Approves Halozyme and J&J Combination Therapy for Multiple Myeloma

Key Facts

1The U.S. FDA approved TECVAYLI in combination with DARZALEX FASPRO for treating adults with relapsed or refractory multiple myeloma (RRMM).

2The approval is based on Phase 3 MajesTEC-3 study data demonstrating significant improvements in progression-free survival and overall survival.

3DARZALEX FASPRO incorporates Halozyme Therapeutics' ENHANZE technology, facilitating subcutaneous administration and improving outcomes.

The U.S. Food and Drug Administration (FDA) has granted approval for the combination of TECVAYLI and DARZALEX FASPRO to treat adults with relapsed or refractory multiple myeloma. This regulatory milestone follows positive results from the Phase 3 MajesTEC-3 study, which demonstrated significant improvements in progression-free and overall survival rates compared to standard care. The treatment utilizes Halozyme Therapeutics' proprietary ENHANZE technology, which facilitates subcutaneous administration of the DARZALEX FASPRO component. This approval is expected to drive significant revenue growth for Johnson & Johnson while providing Halozyme with increased royalty streams from its innovative technology. Investors view the news as a major catalyst for both companies within the oncology and biotechnology sectors, clearing the path for expanded commercialization. The therapy specifically targets patients who have undergone at least one prior line of treatment, broadening the market reach for these pharmaceutical assets.